Chez AbbVie en France, nous nous engageons à favoriser l’insertion des jeunes dans le monde professionnel. En cette #JournéeMondialeDeLaJeunesse, revenons sur quelques-unes de nos initiatives : 👉 mise en place d'AbbVie Possibilities Scolarship : un programme qui propose une bourse jusqu’à 5 000 € pour financer les études des enfants des collaborateurs, étudiants âgés de moins de 26 ans 👉 soutien aux missions de l’@E2C94 - École de la 2e chance du Val de Marne en faveur de l’insertion sociale et professionnelle des jeunes 👉 accueil d'étudiants en #stage ou en #alternance chaque année au sein de tous nos départements Parce que ce sont eux qui en parlent le mieux, la parole à nos jeunes talents ⤵️ 🔗 Pour retrouver l’ensemble de leurs témoignages : https://lnkd.in/epDF2k3z
About us
AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.
- Website
-
http://www.abbvie.com
External link for AbbVie
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- North Chicago, Illinois
- Type
- Public Company
- Specialties
- Biopharmaceutical, Biotechnology, Innovation, Research and Development, Manufacturing, Biotherapeutics, Oncology, Immunology, Virology, Neuroscience, Womens Health, Aesthetics, and Eye Care
Locations
Employees at AbbVie
Updates
-
Earlier this year, our employees across the globe participated in AbbVie In Motion, our annual team-based movement and activity challenge. See how we make employee health and well-being one of our top priorities: https://bit.ly/3yzcby5 #AbbVieLife [Video description: Images and statistics recapping the impact of AbbVie in Motion around the world, including 16K+ participants; 1,400+ teams from 69 countries; more than 25M total physical activity minutes logged.]
-
Thank you to our 13,000+ employees who served their local #communities during Week of Possibilities, the AbbVie Foundation’s annual #volunteer event. Together they spent nearly 50,000 hours contributing to numerous community projects around the globe, including renovating and improving schools, serving meals, building homes, cleaning up waterways and more. See the full impact of their volunteering: https://bit.ly/4dyXFoQ #AbbVieGivesBack [Video description: Interviews with AbbVie employees talking about volunteering during Week of Possibilities and footage of volunteer activities.]
-
How long does it take to bring new #treatments from discovery, to clinical development, and then to patients? The answer: an average of 10-15 years. That’s why we’re challenging conventional timelines to cut that process in half. Learn more: https://bit.ly/3yhUNOq
-
-
NEWS: American Society of Hematology's journal, Blood, published updated results from a Phase 3 study, which includes six-year follow-up data in #patients with previously untreated chronic lymphocytic leukemia (#CLL). Learn more about the findings: https://bit.ly/3LPPUPB [Video description: On-screen text reads, “Oncology News.”]
-
To celebrate our #interns' great work this summer, we hosted a picnic on National Intern Day at our North Chicago HQ. Explore our #internship opportunities and see why we were named to WayUp and Yello.co's list of Top 100 Internship Programs of 2024: https://bit.ly/3WNax5i #AbbVieLife [Video description: Six AbbVie interns jumping over the video frame to transition from their workspace to an outdoor picnic.]
-
Cerevel Therapeutics is now part of AbbVie. Learn how this #acquisition strengthens our #neuroscience pipeline, continuing our mission to transform standards of care across neurological and psychiatric conditions. Explore: https://abbv.ie/53b6c2 $ABBV [Image description: On-screen text reads, "Cerevel is now part of AbbVie. Completion of acquisition adds pipeline of assets to complement our neuroscience portfolio. Click the link to learn more."]
-
We’re striving to make a difference for people impacted by #IBD. Learn how we’re working to reimagine the standards of care through innovation and research: https://abbv.ie/cb1af7 #UlcerativeColitis #CrohnsDisease [Image description: Roopal Thakkar, M.D., EVP, R&D, Chief Scientific Officer, AbbVie, says, "We are committed to strengthening our diversified inflammatory bowel disease (IBD) portfolio, providing healthcare professionals with more options to treat their IBD patients."]
-
ICYMI: Members of our executive leadership team discussed our Q2 2024 #FinancialResults during last week’s #earnings call. Swipe to learn more about our performance from our leaders. $ABBV [Image description: Members of AbbVie’s executive leadership team share their remarks on our Q2 2024 Financial Results, including: Robert A. Michael, Jeffrey R. Stewart, Carrie Strom, Roopal Thakkar and Scott T. Reents.]
-
Millions of people worldwide are living with #HepatitisC. On #WorldHepatitisDay, learn about our commitment to treating #HCV and the role of partnerships to achieve the World Health Organization’s HCV elimination goal by 2030. ⬇ [Video description: Interview with Brian Conway, medical director, Vancouver Infectious Diseases Centre. On-screen text reads, “Globally, an estimated 50 million people have HCV, with about 1 million new infections occurring per year. Join us as we work to help eliminate Hepatitis C.”]
Affiliated pages
Similar pages
Browse jobs
Stock
ABBV
NYSE
20 minutes delay
$190.18
0.25 (0.132%)
- Open
- 190.08
- Low
- 187.7
- High
- 190.57
Data from Refinitiv
See more info on